The use of electronic health records to inform cancer surveillance efforts: a scoping review and test of indicators for public health surveillance of cancer prevention and control

Sarah Conderino¹*, Stefanie Bendik¹, Thomas B. Richards², Claudia Pulgarin¹, Pui Ying Chan³, Julie Townsend², Sungwoo Lim³, Timothy R. Roberts⁴ and Lorna E. Thorpe¹

Abstract

Introduction: State cancer prevention and control programs rely on public health surveillance data to set objectives to improve cancer prevention and control, plan interventions, and evaluate state-level progress towards achieving those objectives. The goal of this project was to evaluate the validity of using electronic health records (EHRs) based on common data model variables to generate indicators for surveillance of cancer prevention and control for these public health programs.

Methods: Following the methodological guidance from the PRISMA Extension for Scoping Reviews, we conducted a literature scoping review to assess how EHRs are used to inform cancer surveillance. We then developed 26 indicators along the continuum of the cascade of care, including cancer risk factors, immunizations to prevent cancer, cancer screenings, quality of initial care after abnormal screening results, and cancer burden. Indicators were calculated within a sample of patients from the New York City (NYC) INSIGHT Clinical Research Network using common data model EHR data and were weighted to the NYC population using post-stratification. We used prevalence ratios to compare these estimates to estimates from the raw EHR of NYU Langone Health to assess quality of information within INSIGHT, and we compared estimates to results from existing surveillance sources to assess validity.

Results: Of the 401 identified articles, 15% had a study purpose related to surveillance. Our indicator comparisons found that INSIGHT EHR-based measures for risk factor indicators were similar to estimates from external sources. In contrast, cancer screening and vaccination indicators were substantially underestimated as compared to estimates from external sources. Cancer screenings and vaccinations were often recorded in sections of the EHR that were not captured by the common data model. INSIGHT estimates for many quality-of-care indicators were higher than those calculated using a raw EHR.

Conclusion: Common data model EHR data can provide rich information for certain indicators related to the cascade of care but may have substantial biases for others that limit their use in informing surveillance efforts for cancer prevention and control programs.
Introduction

Timely and reliable surveillance data is critical to guide efforts to reduce cancer morbidity and mortality, particularly among underserved populations that experience disparities in cancer risk factors, health care services, and outcomes [1–3]. State cancer prevention and control programs rely on surveillance data to understand trends, evaluate the effectiveness of interventions, measure health equity, and distribute resources to the populations at highest risk. While cancer surveillance within the U.S. is relatively robust compared to surveillance for many other chronic conditions, there are several key limitations to current practices. First, prevalence estimates for risk factors and cancer screenings often come from population-based health surveys [3–7], which can be both cost- and time-intensive and can have low validity for self-reported health information [8–13]. Second, although cancer registries provide reliable cancer prevalence and incidence rates, they often lack comprehensive information regarding the full cascade of engagement with the healthcare system from screening to timely initiation of treatment, often referred to as the ‘cascade of care.’ Cancer registries also cannot assess prevention and screening efforts within wider patient populations (e.g., population-level cancer screening rates) [14, 15].

Widespread adoption of electronic health records (EHRs) poses a strategic opportunity to improve upon these limitations in cancer surveillance. EHR data contain a wealth of clinical information, including diagnoses, procedures, lab results, medications, and vitals, which can be accessed in real-time on large convenience samples of in-care patients. In addition, the expansion of health information exchanges or research networks allows for the linkage of EHR data across contributing healthcare institutions. These data systems, which often use common data models to create a standard data format and link patient records across disparate institutions, can provide a more complete representation of care received and a wider geographic coverage than EHR data from a single healthcare institution. These EHR-based systems therefore have potential to produce timely estimates of cancer surveillance indicators along the continuum of the cascade of care. Yet the extent to which EHR networks can be used to generate accurate cancer surveillance metrics remains unknown.

EHR data are currently routinely used to explore and explain patterns in cancer care among patient populations. This includes reporting on clinical quality measures for health systems, such as adherence to cancer-related preventative and screening services [16], as well as epidemiologic and clinical research, such as assessing determinants for non-adherence to cancer guidelines, developing interventions to increase screening and immunization efforts, and identifying delays in care [17–25]. In addition, there has been growing support and adoption of using EHRs to automate and standardize reporting to state central cancer registries [26, 27]. However, utilization of EHR data to inform cancer prevention and control programs has been more limited. To our knowledge, there have been no comprehensive scoping reviews to assess the use of EHR data for cancer surveillance, nor have efforts been made to comprehensively design and test EHR-based cancer surveillance metrics.

To fill these gaps, our study aimed to (1) review the current state of the literature on how EHRs have been used to inform cancer surveillance to date; (2) propose potential surveillance indicators that can be constructed using common data model EHR variables along the spectrum of cancer surveillance: risk factors, screening and immunization, quality of care, and incidence or prevalence; and (3) perform an initial validity test of these proposed indicators. The overall goal of the project was to identify EHR-based cancer surveillance indicators that could be used by state public health programs to set objectives to improve cancer prevention and control, plan public health interventions, and evaluate state-level progress towards achieving those objectives. Here, we define cancer surveillance indicators as measures related to primary (i.e. reducing the incidence of cancer) or secondary prevention (i.e., leading to early diagnosis or prompt treatment of cancer).

Material and methods

Investigation team

An academic-government investigative team led by the New York University and City University of New York (NYU-CUNY) Prevention Research Center (PRC) undertook this investigation. The investigation team included researchers from NYU Grossman School of Medicine, as well as epidemiology and cancer control experts from the New York City (NYC) Department of Health and Mental Hygiene (DOHMH), the New York State (NYS) Department of Health (DOH), and the Centers for Disease Control and Prevention (CDC). The goal of the investigation was to evaluate the feasibility of a model cancer surveillance report on EHR-based performance measures.
that state/territorial/tribal and CDC cancer prevention and control programs could use to plan interventions to improve cancer prevention and control. The start date was September 30, 2019, and the end date was December 31, 2020.

Scoping review

The goal of our initial scoping review was to understand the gaps and potential opportunities of using EHRs for cancer surveillance. Our review was informed by methodological guidance from the PRISMA Extension for Scoping Reviews [28]. In December 2019, co-author TRR, a trained medical librarian, constructed a search using a combination of key words and control vocabulary for articles that discussed any of the selected cancer surveillance indicator and the use of electronic health records or electronic medical records. The search was run in the MEDLINE, EMBASE, and CENTRAL: Registry of Clinical Trials databases using the Ovid Platform, along with Web of Science Core Collection and the Cinahl database on the Ebsco Platform. The complete Search Strategy is included in Additional file 1 of this article. We developed inclusion and exclusion criteria and then iteratively refined them to screen the resulting publications for eligibility in our study. Publications were included if they focused on using EHRs to measure indicators from one or more of nine cancer sites (breast, cervical, colorectal, leukemia, liver, lung, prostate, skin, and uterine) within four cancer surveillance domains (cancer risk factors, screening and immunization, referral to care, and incidence/prevalence). Cancer risk factors were limited to common risk factors for at least one of the nine cancer sites, including alcohol use, BMI/obesity, childhood obesity, diet, family history of cancer, hormone use, HPV incidence, physical activity, smoking cessation, smoking status, and sun exposure. Immunizations were limited to the human papillomavirus (HPV) vaccine and the hepatitis B (HBV) vaccine, which are recommended as primary prevention measures for HPV-associated cancers (including cervical cancer) and liver cancer respectively [29–31]. Additional inclusion criteria were as follows: (1) peer-reviewed primary studies; (2) hospital publications; tip sheets, and briefs (selected grey sources); (3) published from 2009 to 2019. Publications were excluded if they met any of the criteria as follows: (1) not published in English (applied at the full text screening stage); (2) conference proceedings; (3) studies predicting cancer occurrence; (4) tertiary prevention research (e.g., effectiveness of cancer treatments, cancer morbidity or mortality); (5) studies that do not use EHRs as one of the primary data sources for measuring the cancer surveillance indicators under study; (6) studies that did not have a risk factor of interest; (7) studies that focused on a cancer subtype (Fig. 1).

Based on these criteria, publications were screened for eligibility during a two-stage process. First, all identified titles and abstracts underwent independent dual screening to exclude any non-relevant publications. Second, all remaining full-text publications underwent independent

![Scoping review flow diagram, 2012–2019](image)
dual review for eligibility. Reviewers were comprised of a group of seven total reviewers (co-authors SC, SB, TBR, CP, PYC, LT, TRR) who were trained on the review protocol. Disagreements were resolved by consensus or by whichever lead author (SC or SB) was not part of the initial review of the article in conflict. Citations were imported to Covidence software to assist with this eligibility screening review [32]. Resulting full-text publications that were deemed eligible for this study were then imported into a REDCap database for data extraction [33, 34]. The extraction form was iteratively developed and tested to ensure consistency and understanding across reviewers, achieving a final agreement rate of 87.9% within the extracted data on a random sample of five articles. Data from each article were then extracted by a single reviewer, and agreement among reviewers was assessed using dual-review on a sample of 122 articles. Due to the high number of more recent quality studies and the relatively recent maturation of EHR networks in providing quality data, we determined at the data extraction stage that articles would be limited to publications from 2012 to 2019. Data were analyzed using SAS software, Version 9.4 of the SAS System for Windows [35].

**Indicator development**

Concurrently with the scoping review, we selected and tested potential surveillance indicators that could be constructed using common data model EHR variables along the spectrum of cancer surveillance. Proposed surveillance indicators were selected through the review of the literature and a two-round modified Delphi process. The Delphi process is a method in which anonymous responses or opinions are reduced to rapidly reach consensus and to maximize shared decision-making among stakeholder partners [36, 37]. In total, 13 public health practitioners with expertise in cancer prevention or epidemiologic methods from the New York City (NYC) Department of Health and Mental Hygiene (DOHMH), the New York State (NYS) Department of Health (DOH), and the Centers for Disease Control and Prevention (CDC) were identified to participate in this process. Stakeholders were surveyed using Qualtrics software (Version November 2019 of Qualtrics. Copyright © 2019 Qualtrics, Provo, UT, USA. [https://www.qualtrics.com](https://www.qualtrics.com)) to (1) rate potential surveillance indicators for feasibility (i.e., ability to measure using EHR data), actionability (i.e., can be used to forward the mission or responsibilities of their specific agency), and priority (i.e., importance as a public health indicator); (2) prioritize cancer sites; and (3) suggest additional metrics if necessary.

We selected 26 surveillance indicators deemed to be feasible, actionable, and a priority for public health agencies (Table 1). We constructed these measures within an NYC patient population using EHR data from a common data model. Data were obtained for clinical care received between 2008 and 2018 from the INSIGHT Clinical Research Network, which includes medical data for over 11 million patients across five academic medical centers located in NYC [38]. The INSIGHT Clinical Research Network is one of nine National Patient-Centered Clinical Research Networks (PCORnet) throughout the country, which share a common data model of patient- and encounter-level structured data elements from the EHR [39]. INSIGHT data on the population of patients residing in NYC who had an ambulatory care encounter in 2018 were provided to the investigative team through a virtual machine housed at Weill Cornell Medical College. Data conformed to version 5.1 of the PCORnet common data model. Within this NYC-resident patient population data, we iteratively developed rule-based Structured Query Language (SQL) algorithms using standardized codes [International Classification of Disease (ICD)-9-CM and ICD-10-CM diagnostic or procedure codes, Current Procedural Terminology (CPT) codes, Healthcare Common Procedure Coding System (HCPCS) codes, Logical Observation Identifiers Names and Codes (LOINC) laboratory codes], BMI measurements, or smoking status records present in these data (see Additional file 2 for detailed definitions of each indicator).

In addition to producing crude indicators within the full NYC-resident INSIGHT patient population, we also produced estimates that were weighted to reflect the total NYC population, including those who have not visited a healthcare facility, to account for demographic differences between our sample and the larger target population of NYC residents. These data were weighted using post-stratification to the general NYC population, as derived from the 2018 Integrated Public Use Microdata Series (IPUMS) USA data [40]. Post-stratification weights were calculated using NYC population estimates stratified by gender (woman or man), age group (0–4, 5–9, 10–14, 15–17, 18–19, 20–24, 25–29, 30–34, 35–44, 45–54, 55–64, and 65+ years), and neighborhood poverty distribution (percentage living in poverty per Public Use Microdata Area (PUMA): <10%, 10–19%, 20–29%, ≥30%). Within the INSIGHT data, stratum-specific indicator estimates were calculated by equivalent gender and age group variables and by neighborhood poverty distribution as defined by Zip Code Tabulation Area (ZCTA). Confidence intervals were calculated using post-stratification variance estimates, defined as the sum of the variance expected under proportional allocation and the variance expected from post-stratification for each stratum [40].
Validation of proposed indicators

We conducted two initial validity checks of the proposed indicators. First, we compared the crude indicator common data model estimates obtained through INSIGHT data to estimates obtained using the NYU Langone Epic EHR in order to assess potential data loss in the translation of raw EHR data to the PCORnet common data model. Data loss could occur in this translation since not all elements of the EHR are included or conform to this common data model and would therefore not be represented in these data. All indicator SQL queries were developed and tested on NYC-resident patients within the NYU Langone Clarity database, which allows full access to the raw data for the NYU Langone Epic EHR. Prevalence estimates obtained using INSIGHT data were assessed for comparability to those obtained using NYU Langone data using the two one-sided t-tests of equivalence (TOST) and using a prevalence ratio range of 0.85 to 1.50, allowing for this larger upper bound to accommodate the increased capture in INSIGHT as a result of linking patient care across institutions [41, 42].

We then compared weighted prevalence estimates obtained from INSIGHT data to analogous surveillance indicators from external data sources traditionally used for cancer surveillance, with the goal of assessing the general plausibility of the magnitude of the EHR-generated

| Indicator | Description |
|-----------|-------------|
| Adult obesity | The proportion of adults aged 18+ years who are obese |
| Childhood obesity | The proportion of children aged 2–17 years who are obese |
| Smoking | The proportion of adults aged 18+ years who are smokers |
| Breast cancer screening | The proportion of women aged 50–74 years who are up-to-date on breast cancer screening guidelines |
| Cervical cancer screening | The proportion of women aged 21–65 years who are up-to-date on cervical cancer screening guidelines |
| Colorectal cancer screening | The proportion of adults aged 50–75 years who are up-to-date on colorectal cancer screening guidelines |
| Hepatitis C testing | The proportion of adults born between 1945 and 1965 who were tested for hepatitis C |
| HBV vaccination initiation | The proportion of children aged 19–35 months who receive at least one dose of the HBV vaccine |
| HBV vaccination completion | The proportion of children aged 19–35 months who receive three doses of the HBV vaccine |
| HPV vaccination initiation | The proportion of adolescents aged 13–17 years who receive at least one dose of the HPV vaccine |
| HPV vaccination completion | The proportion of adolescents aged 13–17 years who complete the HPV vaccine series |
| Adult obesity | The proportion of adults aged 18+ years who are obese |
| Childhood obesity | The proportion of children aged 2–17 years who are obese |
| Smoking | The proportion of adults aged 18+ years who are smokers |
| Breast cancer screening | The proportion of women aged 50–74 years who are up-to-date on breast cancer screening guidelines |
| Cervical cancer screening | The proportion of women aged 21–65 years who are up-to-date on cervical cancer screening guidelines |
| Colorectal cancer screening | The proportion of adults aged 50–75 years who are up-to-date on colorectal cancer screening guidelines |
| Hepatitis C testing | The proportion of adults born between 1945 and 1965 who were tested for hepatitis C |
| HBV vaccination initiation | The proportion of children aged 19–35 months who receive at least one dose of the HBV vaccine |
| HBV vaccination completion | The proportion of children aged 19–35 months who receive three doses of the HBV vaccine |
| HPV vaccination initiation | The proportion of adolescents aged 13–17 years who receive at least one dose of the HPV vaccine |
| HPV vaccination completion | The proportion of adolescents aged 13–17 years who complete the HPV vaccine series |
| Breast: any diagnostic test | The proportion of women who receive diagnostic follow up after an abnormal screening mammogram |
| Breast: timely diagnostic test | The proportion of women who receive timely diagnostic follow up after an abnormal screening mammogram (within 60 days) |
| Breast: timely diagnosis | The proportion of women with incident breast cancer who receive timely diagnosis after an abnormal screening mammogram (within 60 days) |
| Cervical: any diagnostic test | The proportion of women who receive diagnostic follow up after an abnormal cervical cancer screening |
| Cervical: timely diagnostic test | The proportion of women who receive timely diagnostic follow up after an abnormal cervical cancer screening (within 90 days) |
| Cervical: timely diagnosis | The proportion of women with incident cervical cancer who receive timely diagnosis after an abnormal cervical cancer screening (within 60 days) |
| Colorectal: any diagnostic test | The proportion of adults who receive diagnostic follow up after an abnormal colorectal cancer screening |
| Colorectal: timely diagnostic test | The proportion of adults who receive timely diagnostic follow up after an abnormal colorectal cancer screening (within 90 days) |
| Colorectal: timely diagnosis | The proportion of adults with incident colorectal cancer who receive timely diagnosis after an abnormal colorectal cancer screening (within 90 days) |
| Breast cancer incidence | The incidence proportion of female breast cancer per 1000 patients |
| Breast cancer prevalence | The annual prevalence of female breast cancer per 1000 patients |
| Cervical cancer incidence | The incidence proportion of cervical cancer per 1000 patients |
| Cervical cancer prevalence | The annual prevalence of cervical cancer per 1000 patients |
| Colorectal cancer incidence | The incidence proportion of colorectal cancer per 1000 patients |
| Colorectal cancer prevalence | The annual prevalence of colorectal cancer per 1000 patients |
estimate and hypothesizing any significant sources of information or selection bias that may limit the use of the PCORnet common data model for cancer surveillance purposes. External data sources for these analyses included the NYC Health and Nutrition Examination Survey [43] (2014 physical exam-based adult obesity), NYC FITNESSGRAM [44] (2018 physical-exam based childhood obesity), NYC Community Health Survey [45] (2017 smoking status, 2013 Hepatitis C testing, 2014 breast cancer screening, 2017 cervical and colorectal cancer screening), NYC Citywide Immunization Registry [46, 47] (2018 HBV initiation and 2017 HPV completion), and NYS Cancer Registry [48] (2016 breast, cervical, and colorectal incidence and prevalence). We compared weighted prevalence estimates obtained using INSIGHT data to those reported from external data sources using prevalence ratios.

Results
Scoping review
After removing duplicates, a total of 4059 articles were identified through database searching, of which 816 (20.1%) were deemed eligible for full-text review (Fig. 1). Among these, 415 (50.9%) were excluded following the pre-specified inclusion and exclusion criteria. The top reasons for exclusion were for being the wrong article type (n = 81), having no use of EHRs (n = 71), representing tertiary prevention (n = 51), and for being the wrong study design (n = 47). There was 79.4% agreement among reviewers at the title and abstract review stage and 71.3% agreement at the full-text review stage. Among the sample of 122 articles that underwent dual-review during the extraction phase, there was 87.9% agreement within the extracted data among reviewers. This was deemed high enough to proceed with single reviewer extraction for the remainder of the articles.

Within the final sample of 401 eligible articles, 84.1% were classified as observational studies but only 15.0% were deemed to have a study purpose related to surveillance (Table 2). The majority of studies focused either on epidemiologic research, such as identifying risk factors for lack of adherence with cancer screening guidelines, or on clinical quality improvement, such as the implementation and evaluation of clinical decision support systems. Approximately half of the articles (n = 206) used rule-based algorithms to define their cancer-related variables and 36.8% (n = 144) performed linkages or comparisons of EHR data to other external data sources. The most commonly used clinical data sources within the EHR included diagnoses (31.2%), procedures (17.5%), notes (16.2%), and labs (15.5%). Almost 20% of the articles did not specify the specific clinical sources within the EHR that were used for their study. The majority of studies (n = 287) used data from multiple institutions rather than a single institution, but only 15 articles specified that their data source used a common data model. In addition, while 121 (30.7%) articles specified that standardized codes (e.g., ICD-10 or CPT codes) were used to define their cancer-related variables, only 67 (55.4%) provided the specific codes that were used.

Overall, the majority of studies measured variables from the cancer risk factor (N = 167) and cancer screening or immunization surveillance domains (N = 146). Over half of the articles with a surveillance, epidemiologic, or methodological study purpose measured a cancer risk factor while less than one-third of quality
Cancer risk factor indicators (prevalence of adult obesity, childhood obesity, and the proportion of adults aged 18+ years who are smokers) and eight screening and immunization indicators (prevalence of meeting recommended guidelines for breast cancer screening, cervical cancer screening, colorectal cancer screening, Hepatitis C testing, HBV vaccination initiation and completion, and HPV vaccination initiation and completion). In addition, three quality of care indicators (prevalence of receiving any diagnostic testing, prevalence of receiving timely diagnostic testing, and prevalence of receiving a timely diagnosis after abnormal cancer screenings), as well as incidence and prevalence indicators, were selected for the cancer sites of the breast, cervix, and colon/rectum (Table 1).

A total of 1,844,491 NYC resident INSIGHT patients had an ambulatory care encounter in 2018 and were included in the sample. Over half of these patients were women (59.6%), 32.0% had a missing or unknown race, and 29.3% had a missing or unknown ethnicity. The median patient age was 44 years (IQR: 26–62 years). A total of 604,699 NYC resident NYU Langone patients had an ambulatory care encounter in 2018 and were included in the comparison sample. Similar to the

### Table 3  Cancer-related indicators studied among all scoping review articles and by study purpose

| Total sample (n = 401) | Study purpose |
|-----------------------|----------------|
|                       | Surveillance (n = 60) | Epidemiologic (n = 127) | Methodological (n = 103) | Quality improvement (n = 134) |
| **Cancer risk factor** |                       |                          |                          |                               |
| Adult obesity         | 64 (16.0%)           | 13 (21.7%)               | 29 (22.8%)               | 24 (23.3%)                    | 10 (7.5%)                     | 3 (2.2%)                     | 28 (20.9%)                   |
| Childhood obesity     | 29 (7.2%)            | 15 (25.0%)               | 8 (6.3%)                 | 7 (6.8%)                      | 3 (2.2%)                     | 2 (1.5%)                     | 1 (0.8%)                     |
| Smoking status        | 98 (24.4%)           | 13 (21.7%)               | 46 (36.2%)               | 35 (34.0%)                    | 18 (13.4%)                   | 7 (5.3%)                     | 4 (3.0%)                     |
| Other                 | 52 (13.0%)           | 2 (3.3%)                 | 26 (20.5%)               | 11 (10.7%)                    | 17 (12.7%)                   | 5 (3.9%)                     | 2 (1.5%)                     |
| **Screening and Immunization** |                 |                          |                          |                               |                               |                               |                               |
| Breast cancer screening| 38 (9.5%)           | 6 (10.0%)                | 16 (12.6%)               | 2 (1.9%)                      | 12 (9.0%)                    | 4 (3.0%)                     | 1 (0.8%)                     |
| Cervical cancer screening | 39 (9.7%)       | 8 (13.3%)                | 15 (11.8%)               | 2 (1.9%)                      | 15 (11.2%)                   | 4 (3.0%)                     | 1 (0.8%)                     |
| HPV vaccination        | 38 (9.5%)            | 7 (11.7%)                | 12 (9.5%)                | 2 (1.9%)                      | 21 (15.7%)                   | 5 (3.9%)                     | 1 (0.8%)                     |
| Colorectal cancer screening | 82 (20.5%) | 8 (13.3%)                | 21 (16.5%)               | 16 (15.5%)                    | 36 (26.9%)                   | 8 (6.0%)                     | 4 (3.0%)                     |
| Other                 | 26 (6.5%)            | 10 (16.7%)               | 5 (3.9%)                 | 4 (3.9%)                      | 8 (6.0%)                     |                               |                               |
| **Referral to care**  |                       |                          |                          |                               |                               |                               |                               |
| Breast cancer         | 17 (4.2%)            | 2 (3.3%)                 | 4 (3.2%)                 | 2 (1.9%)                      | 4 (3.0%)                     | 1 (0.8%)                     | 1 (0.8%)                     |
| Cervical cancer       | 11 (2.7%)            | 3 (5.0%)                 | 4 (3.2%)                 | 1 (1.0%)                      | 4 (3.0%)                     | 1 (0.8%)                     | 1 (0.8%)                     |
| Colorectal cancer     | 25 (6.2%)            | 2 (3.3%)                 | 3 (2.4%)                 | 3 (2.9%)                      | 12 (9.0%)                    | 2 (1.5%)                     | 1 (0.8%)                     |
| Other                 | 22 (5.5%)            | 3 (5.0%)                 | 4 (3.2%)                 | 3 (2.9%)                      | 12 (9.0%)                    | 2 (1.5%)                     | 1 (0.8%)                     |
| **Incidence/prevalence** |                   |                          |                          |                               |                               |                               |                               |
| Breast cancer         | 29 (7.2%)            | 2 (3.3%)                 | 14 (11.0%)               | 8 (7.8%)                      | 2 (1.5%)                     | 1 (0.8%)                     | 1 (0.8%)                     |
| Cervical cancer       | 10 (2.5%)            | 2 (3.3%)                 | 6 (4.7%)                 | 2 (1.9%)                      | 1 (0.8%)                     | 1 (0.8%)                     | 1 (0.8%)                     |
| Colorectal cancer     | 39 (9.7%)            | 3 (5.0%)                 | 8 (6.3%)                 | 15 (14.6%)                    | 10 (7.5%)                    |                               |                               |
| Other                 | 42 (10.5%)           | 6 (10.0%)                | 13 (10.2%)               | 16 (15.5%)                    | 11 (8.2%)                    |                               |                               |

*Group totals may not sum to 100% due to ability to select multiple or no categories*
INSIGHT patient population, more than half of these patients were women (58.9%) and a sizable proportion had a missing or unknown race (14.4%) or ethnicity (22.1%). The median patient age of the NYU Langone sample was 48 years (IQR: 29–64 years). These patient populations were older and were over-representative of women as compared to the general NYC population (median age = 36.5 years, 52.3% women).

Cancer risk factor

When applying these indicators to the INSIGHT patient population, approximately one-third of adults and one-quarter of children were classified as obese (Table 4). These prevalence estimates for adult and childhood obesity were highly comparable to prevalence estimates derived using the raw EHR data from the NYU Langone patient population (PR\textsubscript{Adult Obesity} = 1.11, PR\textsubscript{Childhood Obesity} = 1.18). The prevalence of adults aged 18+ years who are smokers within the INSIGHT patient population was

| Indicator | Crude prevalence\(^a\) (95% confidence interval) | Weighted prevalence\(^b\) (95% confidence interval) | Internal validation\(^c\) (Prevalence ratio) | External validation\(^d\) (Prevalence ratio) |
|-----------|-----------------------------------------------|-----------------------------------------------|------------------------------------------|------------------------------------------|
| Risk factors (%) | | | | |
| Adult obesity | 33.4 (33.3–33.5) | 31.3 (31.2–31.5) | 1.11* | 1.02 |
| Childhood obesity | 24.4 (24.1–24.6) | 22.3 (22.0–22.6) | 1.18* | 1.19 |
| Smoking | 10.9 (10.8–10.9) | 11.7 (11.6–11.8) | 1.67* | 0.87 |
| Screening and immunization (%) | | | | |
| Breast cancer screening | 24.2 (24.1–24.4) | 24.1 (24.0–24.2) | 0.54 | 0.32 |
| Cervical cancer screening | 10.6 (10.6–10.7) | 10.7 (10.6–10.7) | 0.23 | 0.13 |
| Colorectal cancer screening | 16.6 (16.5–16.7) | 16.7 (16.6–16.8) | 0.42 | 0.24 |
| Hepatitis C testing | 5.0 (4.9–5.1) | 4.8 (4.8–4.9) | 0.17 | 0.12 |
| HBV vaccination initiation | 35.9 (35.0–36.9) | 35.3 (34.4–36.2) | 0.40 | 0.46 |
| HBV vaccination completion | 8.4 (8.0–8.8) | 7.9 (7.6–8.3) | 0.14 | – |
| HPV vaccination initiation | 21.4 (21.1–21.7) | 21.1 (20.8–21.3) | 0.53 | – |
| HPV vaccination completion | 10.7 (10.5–11.0) | 10.6 (10.3–10.8) | 0.90 | 0.18 |
| Quality of care (%) | | | | |
| Breast: any diagnostic test | 86.8 (86.3–87.2) | 85.9 (85.4–86.4) | 1.31 | – |
| Breast: timely diagnostic test | 86.1 (85.6–86.5) | 85.1 (84.6–85.7) | 1.34 | – |
| Breast: timely diagnosis | 79.2 (76.6–81.8) | 77.8 (74.7–80.8) | 1.08 | – |
| Cervical: any diagnostic test | 48.3 (47.5–49.1) | 46.1 (45.2–47.1) | 0.77 | – |
| Cervical: timely diagnostic test | 40.3 (39.5–41.1) | 38.6 (37.7–39.6) | 0.67 | – |
| Cervical: timely diagnosis | 63.6 (48.8–78.4) | 57.1 (34.7–79.6) | 1.14 | – |
| Colorectal: any diagnostic test | 82.6 (81.4–83.8) | 82.2 (80.8–83.5) | 1.35 | – |
| Colorectal: timely diagnostic test | 21.6 (17.6–25.5) | 21.2 (16.8–25.6) | 1.38 | – |
| Colorectal: timely diagnosis | 72.9 (63.9–82.0) | 68.5 (55.6–81.4) | 0.91 | – |
| Incidence and prevalence (per 1000) | | | | |
| Breast cancer incidence | 4.7 (4.6–4.9) | 4.1 (4.0–4.2) | 0.66 | 3.42 |
| Breast cancer prevalence | 33.1 (32.8–33.5) | 27.4 (27.2–27.6) | 0.91 | 1.52 |
| Cervical cancer incidence | 0.3 (0.3–0.4) | 0.3 (0.3–0.3) | 1.92 | 1.40 |
| Cervical cancer prevalence | 1.8 (1.7–1.9) | 1.6 (1.5–1.6) | 1.11 | 1.78 |
| Colorectal cancer incidence | 1.0 (0.9–1.0) | 0.8 (0.8–0.8) | 0.83 | 1.98 |
| Colorectal cancer prevalence | 5.2 (5.1–5.3) | 4.1 (4.0–4.2) | 1.13 | 1.14 |

\(^a\) Unweighted prevalence within the INSIGHT patient population
\(^b\) Weighted to total NYC population using IPUMS USA 2018 data
\(^c\) Prevalence ratio comparing the crude INSIGHT estimate to the estimate calculated within the NYU patient population using the full NYU EHR
\(^d\) Prevalence ratio comparing the weighted INSIGHT estimate to the reported estimates from external data sources as follows: NYC Health and Nutrition Examination Survey (adult obesity), NYC FITNESSGRAM (childhood obesity), NYC Community Health Survey (breast, cervical, and colorectal cancer screening), NYC Citywide Immunization Registry (HBV initiation and HPV completion), and NYS Cancer Registry (breast, cervical, and colorectal incidence and prevalence)

*Internal validation found to be statistically equivalent through the two one-sided t-tests of equivalence using a 5-point equivalence margin
10.9%, which was moderately higher than the prevalence of adults aged 18–35 years who are smokers within the NYU Langone patient population (PR = 1.67). Weighting through post-stratification to the NYC population led to a slight decrease in obesity prevalence estimates and a slight increase in the smoking prevalence estimate. The weighted prevalence estimates were highly comparable to estimates from external physical exam- or survey-based data sources (PRAdult Obesity = 1.02, PRCervical Obesity = 1.19, PRSmoking = 0.87).

**Screening and immunization**

Less than one-quarter of INSIGHT common data model patients met the breast, cervical, and colorectal cancer screening recommendations (Table 4). The common data model prevalence estimates were significantly lower than estimates defined within NYU Langone patients using the raw EHR (PRBreast = 0.54, PCervical = 0.23, PColorectal = 0.42) (Table 4). Notably, a sizable proportion of NYU Langone patients had their cancer screenings recorded in the health maintenance module, a section of the EHR where clinicians can document and track receipt of preventative services, but not within standardized diagnosis or procedure codes (Breast: 13.8%, Cervical: 14.5%, Colorectal: 15.9%).

Weighting the INSIGHT data to the NYC population did not have a large impact on these estimates and they remained substantially underestimated as compared to self-reported prevalence estimates from external health surveys (PRBreast = 0.32, PCervical = 0.13, PColorectal = 0.24). Similarly, the prevalence estimates for Hepatitis C testing, HBV vaccination initiation and completion, and HPV vaccination initiation and completion were significantly lower than estimates defined within the NYU Langone patient population and remained substantially lower than estimates from external data sources after weighting to the demographic distribution of the NYC population (PRHepatitis C = 0.12, PRHBV Initiation = 0.46, PRHPV Completion = 0.18). A sizable proportion of NYU Langone patients who initiated the HBV or HPV vaccination series had their vaccine recorded within the immunizations module of the EHR but not within standardized procedure codes (HBV: 73.2%, HPV: 27.9%).

**Quality of care**

Within the INSIGHT common data model, prevalence estimates for the quality of care indicators were generally higher than estimates produced within the NYU Langone patient population using the raw EHR (Table 4). However, the diagnostic testing indicators for cervical cancer and the timely diagnosis indicator for colorectal cancer were lower than estimates produced within the NYU Langone patient population (Cervical:

**Incidence and prevalence**

Cervical and colorectal cancer incidence and prevalence estimates in the INSIGHT common data model were generally higher than estimates within the NYU Langone patient population, while breast cancer incidence and prevalence were lower (PRIncidence = 0.66, PRPrevalence = 0.91). Weighting to the demographic distribution of the NYC population led to a slight decrease in the INSIGHT breast, cervical, and colorectal cancer incidence and prevalence estimates, but they remained substantially overestimated as compared to reported rates from the NYS Cancer Registry.

**Discussion**

Our scoping review provided a robust number of studies that explored a diversity of topics along the cancer cascade of care. To our knowledge, this is the first scoping review to provide a comprehensive overview of the EHR-based cancer literature starting from the recent maturation of EHR networks. Importantly, this literature base was critical for informing our indicator development work by providing our stakeholders with an understanding of the feasibility and acceptability of using EHRs to measure these types of indicators and by providing variable definitions that we could attempt to replicate or improve upon in this work.

However, we identified a number of gaps in the current literature regarding the use of EHRs to inform cancer prevention and control programs. Although we identified many articles that measured variables related to the cancer cascade of care using EHRs, few had an explicit purpose of informing cancer surveillance efforts. Articles that focused on quality improvement or epidemiologic research generally did not address issues related to selection biases or the representativeness of patient samples, a key challenge for using these data for surveillance efforts. Those that did examine EHR-based measures from the lens of public health surveillance were more likely to incorporate methods or validation approaches to address issues of population representativeness in their samples, but these studies were predominantly focused on cancer risk factors [49–54, 68–70]. In addition, while most studies provided clear conceptual definitions of their EHR-based variables (e.g., receipt of a screening mammogram within the prior two years), a considerable proportion did not include practical definitions, such as use
of a common data model, specific clinical sources within 
the EHR, or standardized codes/terminology. This lack of 
information could limit the replicability of these studies. 

In our development of the proposed indicators for 
public health surveillance of cancer prevention and con-

tral, we attempted to fill these gaps by assessing mea-

sures along the cascade of care, from cancer risk factors 
to cancer incidence and prevalence, and by providing 
clear definitions that are directly transportable to PCOR-

net research networks and adaptable to other EHR data 

sources (Additional file 2). We also tested post-stratifica-
tion methods to account for the demographic differences 
between patient samples and target populations and 

assessed the external validity of these measures. Impor-
tantly, we found that the validity of the PCORnet com-

mon data model-based cancer surveillance indicators 
varied substantially. Among the domains of surveillance 
indicators, estimates for cancer risk factors generally 
showed the best performance, likely due to measure-

ment of obesity and smoking status at the majority of 

medical encounters. Estimates were comparable between 
the PCORnet common data model and a raw EHR and 

were similar or only slightly higher than estimates from 

external surveillance sources. These findings align with 

previous studies identified in the scoping review, which 

demonstrated that EHR-based obesity and smoking indi-
cators were comparable to estimates from established 

surveillance data systems after weighting or adjusting for 
demographic differences between the patient and target 
populations [66–70].

In contrast to cancer risk factors, the unweighted and 

weighted estimates generated for the screening and 

immunization indicators demonstrated poor perfor-

mance, with substantial underestimation as compared to 
estimates generated using a raw EHR. Within the NYU 

Langone sample, we saw that many patients had docu-

mentation of their screenings and vaccinations within 

the health maintenance or immunization modules but not 

within standardized diagnosis or procedure codes. This 

lower prevalence within the common data model 
estimates may be largely attributable to the exclusion of 
certain components of the EHR from the PCORnet com-
mon data model, which largely relies on structured vari-

ables and standardized codes [71]. Further, this highlights 

the importance of directly specifying the sources of cli-
cinal data from within the EHR, as information may not 

be consistently captured or recorded throughout the system. 

More importantly, EHR-derived estimates for screening 
and immunization (from either raw EHR or PCORnet 
common data model) were much lower than estimates 

from traditional surveillance data sources, indicating 

that controlling for demographic differences alone was 

insufficient to address the substantial underestimation 

of these indicators within EHR data. This underestima-
tion may be reflective of patients receiving preventative 

services at outpatient practices that are not affiliated with 
large hospital systems or clinical research networks.

We found that common data model estimates were 

actually higher than those calculated using a raw EHR 

for many of the quality of care indicators. These results 
demonstrate the potential benefits of using health infor-
mation exchanges or research networks, which can 

increase capture if patients receive care across multi-
ple institutions. This benefit may be more apparent for 

quality of care indicators than preventative care indi-
cators since these services may be more likely to occur in 
hospital-based settings. We were unable to externally 

validate these indicators, as there is no established NYC-

based surveillance system that tracks timely diagnostic 
testing and diagnosis after abnormal cancer screenings. 

Using EHRs to monitor quality of cancer care represents 
a unique opportunity to fill this gap, and the few studies 
that we identified as related to this goal demonstrated 
that EHR data could provide valuable insights into trends 
and patterns in cancer care [72–74].

Cancer incidence and prevalence within the INSIGHT 

population was variably higher or lower than incidence 

and prevalence within the NYU Langone population. 

This may reflect underlying differences in patterns of 
care, where NYU Langone may provide care for a dis-

proportionate share of breast cancer patients while other 

organizations within the INSIGHT network may pro-

vide care for a disproportionate share of cervical can-
cer patients in NYC. In our external validation of these 

indicators, the weighted estimates for the incidence and 

prevalence indicators were substantially overestimated as 

compared to rates reported in the NYS Cancer Registry. 

However, prior studies that validated EHR-based cancer 
cases by directly linking these data to cancer registries 
demonstrated reduced sensitivity of EHRs as compared 
to registries [55, 57–59]. This overestimation in our 

weighted estimates is therefore likely related to the cal-
culation of incidence and prevalence rates within sicker 
patient populations, which presented a selection bias 
that could not be remedied by controlling for demo-

graphic differences alone.

Limitations to our scoping review include the use of a 
single reviewer during the data extraction portion of this 
study, which limited our ability to assess potential incons-

istencies in how the reviewers extracted the data. How-
ever, an 87% agreement between two reviewers on a large 

sample of articles mitigated this concern. We also did not 

publish the scoping review protocol and excluded arti-
cles published from 2009 to 2011 during data extraction 
based on the decreased relevancy and utility of articles as 
we went further back in time. Limitations to the indicator
development include our inability to use race/ethnicity in our weighting approach due to the high proportion of INSIGHT patients who had an unknown or other race/ethnicity. Numerous articles identified through the scoping review demonstrated patterns in these cancer indicators by race/ethnicity [69, 70, 75–77], so our weighted estimates likely contain residual biases due to the racial/ethnic distribution in this patient population. Our weighting approach also only incorporated demographic variables, which likely cannot fully account for the systematic differences between patient populations and the general population. In addition, while we provide initial validation results, we did not formally evaluate the internal validity of our indicators through manual chart review and many of our indicators lack a true gold standard by which to externally validate these measures. Our data were also restricted to version 5.1 of the PCORnet common data model. More recent versions of this common data model have included provider specialty and qualitative lab results, which would likely improve the estimation of preventative services, like cancer screenings, using these data.

Conclusions
In conclusion, a review of the current literature suggests that future research on the use of EHRs for cancer surveillance will benefit from careful reporting of key information such as provision of EHR definitions, standardized codes and common data model correlates, as well as description of data quality and bias correction measures taken. Effort could be made to improve the PCORnet common data model for surveillance purposes, such as through improved reporting of race/ethnicity and through the inclusion of additional sources of preventative health services information from raw EHRs. Future studies could also consider limiting patient cohorts to those seen by primary care providers and incorporating additional variables, like insurance status, into weighting or adjustment strategies to better address the biases we observed in this study. Local, state, territorial, and national public health agencies have a strategic opportunity to use timely and geographically granular EHR data for select indicators for public health surveillance of cancer prevention and control, such as cancer risk factors, to assist in planning interventions to improve cancer prevention and control. These data can also potentially provide more accessible and richer information on the cascade of cancer care than routine surveillance data systems. However, these data currently cannot be used to monitor screening and immunization or cancer incidence and prevalence due to the biases we observed for these indicators. Further research is needed to address issues related to population representativeness of these convenience samples.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12911-022-01831-8.

Additional file 1. Ovid MEDLINE search Run December, 5, 2019
Additional file 2. Indicator definitions

Acknowledgements
Thank you to Justin M. Feldman, Simona C. Kwon, and Barbara Wallace (New York State Department of Health) for their contributions to the pilot demonstration project.

Author contributions
SC wrote the main manuscript text and performed the analyses. SC, SB, TBR, CP, PVC, TRR, and LET participated in the scoping review. TBR, JT, PVC, and SL participated as stakeholder partners in designing the pilot demonstration project. LET conceptualized and designed the project. All authors read and approved the final manuscript.

Funding
This project was supported by Centers for Disease Control and Prevention. Prevention Research Program Special Interest Project 19-008, National Center for Chronic Disease Prevention and Health Promotion (New York University Cooperative Agreement Application # 3U48 DP006396-01S).

Availability of data and materials
Data are housed at Weill Cornell due to personal health information. Please contact Sarah Conderino (sarah.conderino@nyulangone.org) for requests related to materials.

Declarations
Ethics approval and consent to participate
The study was approved by the New York University School of Medicine Institutional Review Board and waived informed consent.

Consent for publication
Not applicable.

Disclaimer
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Competing interests
The authors declare that they have no conflict of interest to disclose.

Author details
1Department of Population Health, New York University Grossman School of Medicine, 180 Madison Ave, New York, NY 10016, USA. 2Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. 3Division of Epidemiology, New York City Department of Health and Mental Hygiene, Long Island City, NY 11101, USA. 4Health Sciences Library, New York University Grossman School of Medicine, New York, NY 10016, USA.

Received: 5 November 2021 Accepted: 27 March 2022
Published online: 06 April 2022
References

1. Fang P, He W, Giordano S, Smith GL. Racial disparities in guideline-concordant cancer care. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):S10.

2. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017; racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–48.

3. Sabatino SA, White MC, Thompson TD, Klabunde CN, Centers for Disease Control and Prevention. Cancer screening test use - United States, 2013. MMWR Mortal Mortal Wkly Rep. 2015;64(17):464–8.

4. Ryerson AB, Massetti GM. CDC’s public health surveillance of cancer. Prev Chronic Dis. 2017;14:E39-E.

5. Los Angeles County Health Survey. Los Angeles, CA. County of Los Angeles Department of Public Health; 2015.

6. New York City Community Health Survey. New York, NY. New York City Department of Health and Mental Hygiene; 2017.

7. Boston Behavioral Risk Factor Surveillance System. Boston, MA. Boston Public Health Commission; 2016.

8. Thorpe LE. Surveillance as our sextant. Am J Public Health. 2017;107(6):847–8.

9. Galea S, Tracy M. Participation rates in epidemiologic studies. Ann Epidemiol. 2007;17(9):643–53.

10. Lafiame DM, Vandenlice JA. Using the Behavioral Risk Factor Surveillance System (BRFSS) for exposure tracking: experiences from Washington State. Environ Health Perspect. 2004;112(14):1428–33.

11. Bowlin SJ, Morrill BD, Nafziger AN, Jenkins PL, Lewis C, Pearson TA. Validity of cardiovascular disease risk factors assessed by telephone survey: The behavioral risk factor survey. J Clin Epidemiol. 1995;48(6):561–71.

12. Merrill RM, Richardson JS. Validity of self-reported height, weight, and body mass index: findings from the National Health and Nutrition Examination Survey, 2001–2006. Prev Chronic Dis. 2009;6(4):A121-A.

13. Gillum R, Semos CT. Ethnic variation in validity of classification of overweight and obesity using self-reported weight and height in American women and men: the Third National Health and Nutrition Examination Survey. Nutr J. 2005;4(1):27.

14. Mallin K, Pais BC, Watroba N, Stewart AK, Walczak D, Singer J, et al. Completeness of American Cancer Registry Treatment Data: implications for quality of care research. Am J Coll Surg. 2013;216(3):428–37.

15. Tai CG, Schrag D, Deapen D, Blayney DW, Malin J, Santa J, et al. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. J Natl Cancer Inst. 2015;107(5):dyo047.

16. Kern LM, Malhotra S, Barron Y, Quaresimo J, Dhopheshwarak R, Richardo M, et al. Accuracy of electronically reported “meaningful use” clinical quality measures: a cross-sectional study. Ann Intern Med. 2013;158(2):77–83.

17. Wong CA, Taylor JA, Wright OA, Opel DJ, Katzenellenbogen RA. Missed opportunities for adolescent vaccination, 2006–2011. J Adolesc Health. 2013;53(4):492–7.

18. Thompson CA, Gomez SL, Chan A, Chan JK, McClellan SR, Chung S, et al. Patient and provider characteristics associated with colorectal, breast, and cervical cancer screening among Asian Americans. Cancer Epidemiol Biomarkers Prev. 2014;23(11):2208–17.

19. Cowburn S, Carlson M, Lapidos J, Heintzman J, Bailey S, DeVoe J. Insurance continuity and human papillomavirus vaccine uptake in Oregon and California federally qualified health centers. Am J Public Health. 2014;104(9):e71–9.

20. Murphy DR, Laxminar A, Reis BA, Thomas EJ, Esquivel A, Forjucn SN, et al. Electronic health record-based triggers to detect potential delays in cancer diagnosis. BMJ Qual Saf. 2014;23(1):8–16.

21. Murphy DR, Meyer AND, Vaghani V, Russo E, Sittig DF, Wei L, et al. Electronic triggers to identify delays in follow-up of mammography: harnessing the power of big data in health care. J Am Coll Radiol. 2018;15(2):287–95.

22. Murphy DR, Meyer AND, Vaghani V, Russo E, Sittig DF, Wei L, et al. Development and validation of trigger algorithms to identify delays in diagnostic evaluation of gastroenterological cancer. Clin Gastroenterol Hepatol. 2018;16(1):90–8.

23. Murphy DR, Thomas EJ, Meyer AND, Singh H. Development and validation of electronic health record-based triggers to detect delays in follow-up of abnormal lung imaging findings. Radiology. 2015;277(1):81–7.

24. Baker DW, Brown T, Buchanan DR, Weil J, Bailey K, Ranalli L, et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial adherence to annual colorectal cancer screening adherence to annual colorectal cancer screening. JAMA Intern Med. 2014;174(8):1235–41.

25. Ruffin MT, Pligue MA, Rockwell PG, Young AP, Patel DA, Yeazel MW. Impact of an electronic health record (EHR) reminder on human papillomavirus (HPV) vaccine initiation and timely completion. J Am Board Fam Med. 2015;28(3):324–33.

26. Blumenthal W, Alimi TO, Jones SF, Jones DE, Rodgers JD, Benard VB, Richardson LC. Using informatics to improve cancer surveillance. J Am Med Inform Assoc. 2020;27(9):1488–95. https://doi.org/10.1093/jamia/ocaa149.

27. Tangka FK, Edwards P, Pordell P, Wilson R, Blumenthal W, Jones SF, Jones M, Beizer J, Bernacet A, Cole-Beebe M, Subramanian S. Factors affecting the adoption of electronic data reporting and outcomes among selected central cancer registries of the national program of cancer registries. JCO Clin Cancer Inform. 2021;5:921–32. https://doi.org/10.1200/CCI.21.00083.

28. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.

29. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405–8.

30. Meites E. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698–702.

31. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67(1):1–31.

32. Covidence systematic review software. Melbourne, Australia: Ventas Health Innovation.

33. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The Third National Health and Nutrition Examination Survey. Nutr J. 2005;4(1):27.

34. Mallin K, Pais BC, Watroba N, Stewart AK, Walczak D, Singer J, et al. Completeness of American Cancer Registry Treatment Data: implications for quality of care research. Am J Coll Surg. 2013;216(3):428–37.

35. Tai CG, Schrag D, Deapen D, Blayney DW, Malin J, Santa J, et al. Leveraging state cancer registries to measure and improve the quality of cancer care: a potential strategy for California and beyond. J Natl Cancer Inst. 2013;105(7):dyo047.

36. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi and snow card techniques to build consensus among diverse platform partners. J Biomed Inform. 2019;95:103208.

37. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research information. J Biomed Inform. 2009;42(2):377–81.

38. SAS Institute Inc. The SAS system for Windows. 9.4 ed. Cary, NC: SAS Inst.; 2017.

39. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research methodology for nursing. Int J Nurs Stud. 2001;38(2):195–200.

40. Ridout C, Gil R, Browne C, Calhoon C, Rey M, Gourevitch M, et al. Using the Delphi and snow card techniques to build consensus among diverse community and academic stakeholders. Prog Community Health Partnersh. 2013;7(3):311–9.

41. INSIGHT Clinical Research Network. https://insightcrn571888965.wpcomstaging.com/. Accessed 29 Oct 2021.

42. PCORNet. https://www.pcorinet.org/.

43. Thompson SK. Sampling. 3rd ed. New York: Wiley; 2012.

44. Baker DW, Brown T, Buchanan DR, Weil J, Bailey K, Ranalli L, et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial adherence to annual colorectal cancer screening adherence to annual colorectal cancer screening. JAMA Intern Med. 2014;174(8):1235–41.

45. Ruffin MT, Pligue MA, Rockwell PG, Young AP, Patel DA, Yeazel MW. Impact of an electronic health record (EHR) reminder on human papillomavirus (HPV) vaccine initiation and timely completion. J Am Board Fam Med. 2015;28(3):324–33.

46. Baker DW, Brown T, Buchanan DR, Weil J, Bailey K, Ranalli L, et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial adherence to annual colorectal cancer screening adherence to annual colorectal cancer screening. JAMA Intern Med. 2014;174(8):1235–41.
47. Hinterland KNM, King L, Lewin V, Myerson G, Noumbissi B, Woodward M, Gould LH, Gwynn RC, Barbot O, Bassett MT. Community Health Profiles 2018, Brooklyn Community District 1: Greenpoint and Williamsburg. 2018; 25(59):1–20.

48. NYS Cancer Registry and Cancer Statistics: New York State Department of Health. 2016. https://www.health.ny.gov/statistics/cancer/registry/.

49. Gutilla MJ, Davidson AJ, Daley MF, Anderson GB, Marshall JA, Magzamen H. Ready to submit your research? Choose BMC and benefit from:

- maximum visibility for your research: over 100M website views per year
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

50. Wen X, Gillman MW, Rifas-Shiman SL, Sherry B, Kleinman K, Taveras EM. Decreasing prevalence of obesity among young children in Massachusetts from 2004 to 2008. Pediatrics. 2012;129(5):823–31.

51. Dhalwani NN, Tata LJ, Coleman T, Fiaschi L, Szatkowski L. A comparison of UK primary care data with other national data sources for monitoring the prevalence of smoking during pregnancy. J Public Health. 2014;37(3):547–54.

52. Figgatt M, Chen J, Capper G, Cohen S, Washington R. Chronic Disease surveillance using electronic health records from health centers in a large urban setting. J Public Health Manag Pract. 2021;27(2):186–92.

53. Rigobon AV, Birtwhistle R, Khan S, Barber D, Biro S, Morkem R, et al. Adult obesity prevalence in primary care users: An exploration using Canadian Primary Care Sentinel Surveillance Network (CPSSCN) data. Can J Public Health. 2015;106(5):e283–9.

54. Bailey LC, Milov DE, Kelleher K, Kahn MG, del Beccaro MC, Yu F, et al. Multi-institutional sharing of electronic health record data to assess childhood obesity. PLoS ONE. 2013;8(6):e66192.

55. Goldsbury D, Weber M, Yap S, Banks E, O’Connell DL, Canfell K. Identifying incident colorectal and lung cancer cases in health service utilization databases in Australia: a validation study. BMC Med Inform Decis Mak. 2017;17(1):23.

56. Nguyen E, Mehta S, Yates SW, Schrader MK, Martin MC. Colon cancer screening in concierge practice. South Med J. 2017;110(6):408–11.

57. Marquilius AV, Fortuny J, Kaye JA, Calingaert B, Reynolds M, Plana E, et al. Validation of cancer cases using primary care, registry, and hospitalization data in the United Kingdom. Epidemiology. 2018;29(2):308–13.

58. Ruppert LP, He J, Martin J, Eckert G, Ouyang F, Church A, et al. Linkage of Indiana State Cancer Registry and Indiana Network for Patient Care Data. J Registry Manag. 2016;43(4):174–8.

59. Sollie A, Sijmons RH, Helsper C, Numans ME. Reusability of coded data in the primary care electronic medical record: a dynamic cohort study concerning cancer diagnoses. Int J Med Inform. 2017;99:45–52.

60. Filipp SL, Cardel M, Hall J, Essner RZ, Lemas DJ, Janicke DM, et al. Characterization of adult obesity in Florida using the OneFlorida clinical research consortium. Obesity Sci Pract. 2018;4:308–17.

61. Perlman SE, McVeigh KH, Thorpe LE, Jacobson L, Greene CM, Gwynn RC. Innovations in population health surveillance: using electronic health records for chronic disease surveillance. Am J Public Health. 2017;107(6):853–7.

62. Odegan A, Moller H, Murray-Thomas T, Gullford MC. Validity of cancer diagnosis in a primary care database with linked cancer registrations in England. Population-based cohort study. Cancer Epidemiol. 2012;36(5):425–9.

63. Charlton R, Snowball J, Bloomfield K, de Vries C. Colorectal cancer incidence on the General Practice Research Database. Pharmacoepidemiol Drug Saf. 2012;21(7):775–83.

64. Booth HP, Prevost AT, Gullford MC. Validity of smoking prevalence estimates from primary care electronic health records compared with national population survey data for England, 2007 to 2011. Pharmacoepidemiol Drug Saf. 2013;22(12):1357–61.

65. Linder JA, Rogetti NA, Bravarsky P, Kontos EZ, Park ER, Klingler EV, et al. Use of practice-based research network data to measure neighborhood smoking prevalence. Prev Chronic Dis. 2013;10:E84.

66. Klompas M, Cocoros NM, Menchaca JT, Erani D, Hafer E, Herrick B, et al. State and local chronic disease surveillance using electronic health record systems. Am J Public Health. 2017;107(9):1406–12.

67. Szatkowski L, Lewis S, McNeill A, Huang Y, Coleman T. Can data from primary care medical records be used to monitor national smoking prevalence? J Epidemiol Community Health. 2012;66(9):791–5.

68. McVeigh KH, Newton-Dame R, Chan PY, Thorpe LE, Schreibstein L, Tatem KS, et al. Can electronic health records be used for population health surveillance? Validating population health metrics against established survey data. EGEMS. 2016;4(1):1267.

69. Flood TL, Zhao Y-Q, Tomayko EJ, Tandias A, Carrel AL, Hanahan LP. Electronic health records and community health surveillance of childhood obesity. Am J Prev Med. 2015;48(2):234–40.

70. Funk LM, Shon Y, Vois M, Klok J, Hanahan LP. Electronic Health Record Data Versus the National Health and Nutrition Examination Survey (NHANES): a comparison of overweight and obesity rates. Med Care. 2017;55(6):598–605.

71. Garza M, Del Fió G, Tenenbaum J, Walden A, Zozu MN. Evaluating common data models for use with a longitudinal community registry. J Biomed Inform. 2016;64:333–41.

72. Misra-Hebert AD, Hu B, Klein EA, Stephenson A, Taksl G, Battal MW, et al. Prostate cancer screening practices in a large, integrated health system. 2007–2014. BJU Int. 2017;120(2):257–64.

73. Wallner LP, Hsu J-WY, Loo RK, Palmer-Toy DE, Schottinger JE, Jacobsen SJ. Trends in prostate-specific antigen screening, prostate biopsies, urology visits, and prostate cancer treatments from 2000 to 2012. Urology. 2015;86(3):498–505.

74. Raman SR, Brown JS, Curtis L, Haynes K, Marshall J, Pawloski PA, et al. Cancer screening results and follow-up using routinely collected electronic health data: estimates for breast, colon, and cervical cancer screenings. J Gen Intern Med. 2019;34(3):341–3.

75. Porter KR, Hsu JW, Chien GW, Xiang AH, Jung H, Chao C, et al. Racial and ethnic differences in time to treatment for patients with localized prostate cancer. Urology. 2013;81(2):283–7.

76. Kharbanda EO, Parker E, Nordin JD, Hedblom B, Rolnick SJ. Receipt of human papillomavirus vaccine among privately insured adult women in a U.S. Midwestern Health Maintenance Organization. Prev Med. 2013;57(5):712–4.

77. Kantrow SP, Jolley SE, Price-Haywood EG, Wang X, Tseng T-S, Arnold D, et al. Using the emergency department to investigate smoking in young adults. Ann Epidemiol. 2019;30:44-9.e1.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.